08 December 2025
08 December 2025
Opinions were divided on the continued use of the hepatitis B vaccine in a paediatric population.
The partnership includes regional rights to Crescent’s bispecific antibody and Kelun’s ADC.
The deal is anticipated to be finalised in the first quarter of 2026, pending the fulfilment of all closing conditions.
The partnership is intended to expedite R&D in small and large-molecule analysis.
Completion of the agreement remains contingent on several closing conditions.
The pharma industry has called the IRA “price setting” and argues that negotiations have not cut out-of-pocket costs for patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
